Little is known about the relative contribution of comorbidities in predicting the health-related quality of life (HRQoL) of people with Multiple Sclerosis (PwMS).
To determine the associations between the number of and individual comorbidities and HRQoL and estimate the relative contribution of different comorbidities on HRQoL.
Cross-sectional analysis of data on self-reported presence of 30 comorbidities and HRQoL from the Australian MS Longitudinal Study (AMSLS) participants (n = 902). HRQoL was measured using the Assessment of Quality of Life-8 Dimensions (AQoL-8D). Linear regression and general dominance analysis were used.
Higher number of comorbidities was associated with lower HRQoL (p trend p < 0.01). Comorbidities accounted for 18.1% of the variance in HRQoL. Mental health and musculoskeletal disorders were the strongest contributors to lower HRQoL. Of individual comorbidities, systemic lupus erythematosus (SLE) [β = − 0.16 (− 0.27, − 0.05)] and depression [β = − 0.15(− 0.18, − 0.13)] were most strongly associated with overall HRQoL, depression [β = − 0.14(− 0.16, − 0.11)] and anxiety [β = − 0.10 (− 0.13, − 0.07)] with psychosocial HRQoL, and SLE [β = − 0.18 (− 0.29, − 0.07)], rheumatoid arthritis [β = − 0.11 (− 0.19, − 0.02)] and hyperthyroidism [β = − 0.11 (− 0.19, − 0.03)) with physical HRQoL.
Comorbidities potentially make important contributions to HRQoL in PwMS. Our findings highlight groups of and individual comorbidities that could provide the largest benefits for the HRQoL of PwMS if they were targeted for prevention, early detection, and optimal treatment.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
World Health Organization (1997) WHOQOL: measuring quality of life. https://www.who.int/healthinfo/survey/whoqol-qualityoflife/en/. Accessed 12 June 2018
MS International Federation What influences quality of life with MS and how can we improve it? MS International Federation. https://www.msif.org/living-with-ms/what-influences-quality-of-life/. Accessed 27 June 2018
Nortvedt MW, Riise T, Myhr KM, Nyland HI (1999) Quality of life in multiple sclerosis: Measuring the disease effects more broadly. Neurology 53(5):1098–1103
Warren SA, Turpin KVL, Pohar SL, Jones CA, Warren KG (2009) Comorbidity and health-related quality of life in people with multiple sclerosis. Int J MS Care 11(1):6–16
Janzen W, Turpin KVL, Warren SA, Marrie RA, Warren KG (2013) Change in the health-related quality of life of multiple sclerosis patients over 5 years. Int J MS Care 15(1):46–53
Ahmad H, Taylor BV, Ivd M, Colman S, O'Leary BA, Breslin M, Palmer AJ (2017) The impact of multiple sclerosis severity on health state utility values: evidence from Australia. Mult Scler J 23(8):1157–1166
Marrie RA, Horwitz R, Cutter G, Tyry T (2012) Cumulative impact of comorbidity on quality of life in MS. Acta Neurol Scand 125(3):180–186. https://doi.org/10.1111/j.1600-0404.2011.01526.x
Hermann BP, Vickrey B, Hays RD, Cramer J, Devinsky O, Meador K, Perrine K, Myers LW, Ellison GW (1996) A comparison of health-related quality of life in patients with epilepsy, diabetes and multiple sclerosis. Epilepsy Res 25(2):113–118
Berrigan LI, Fisk JD, Patten SB, Tremlett H, Wolfson C, Warren S, Fiest KM, McKay KA, Marrie RA, For the CIHR Team in the Epidemiology Impact of Comorbidity on Multiple Sclerosis (ECoMS) (2016) Health-related quality of life in multiple sclerosis: Direct and indirect effects of comorbidity. Neurology 86(15):1417–1424. https://doi.org/10.1212/WNL.0000000000002564
Turpin KVL, Carroll LJ, Cassidy JD, Hader WJ (2007) Deterioration in the health-related quality of life of persons with multiple sclerosis: the possible warning signs. Mult Scler J 13(8):1038–1045
Weiland TJ, De Livera AM, Brown CR, Jelinek GA, Aitken Z, Simpson SL, Neate SL, Taylor KL, O'Kearney E, Bevens W, Marck CH (2018) Health outcomes and lifestyle in a sample of people with multiple sclerosis (HOLISM): longitudinal and validation cohorts. Front Neuro. https://doi.org/10.3389/fneur.2018.01074
Taylor BV, Palmer A, Simpson S Jr, Lucas R, Group NS, Simmons RD, Mason D, Pearson J, Clarke G, Sabel C, Willoughby E, Richardson A, Abernethy D (2013) Assessing possible selection bias in a national voluntary MS longitudinal study in Australia. Mult Scler J 19(12):1627–1631. https://doi.org/10.1177/1352458513481511
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302. https://doi.org/10.1002/ana.22366
McDonald WI, Compston A, Edan G, Goodkin D, Hartung H-P, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, Svd N, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1):121–127. https://doi.org/10.1002/ana.1032
Marrie RA, Cohen J, Stuve O, Trojano M, Sorensen PS, Reingold S, Cutter G, Reider N (2015) A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview. Mult Scler J 21(3):263–281. https://doi.org/10.1177/1352458514564491
Kang JH, Chen YH, Lin HC (2010) Comorbidities amongst patients with multiple sclerosis: a population-based controlled study. Eur J Neurol 17(9):1215–1219. https://doi.org/10.1111/j.1468-1331.2010.02971.x
Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T (2008) Comorbidity, socioeconomic status and multiple sclerosis. Mult Scler 14:1091–1098. https://doi.org/10.1177/1352458508092263
Richardson J, Sinha K, Iezzi A, Khan MA (2014) Modelling utility weights for the Assessment of Quality of Life (AQoL)-8D. Qual Life Res 23(8):2395–2404
Campbell JA, Hensher M, Neil A, Venn A, Otahal P, Wilkinson S, Palmer AJ (2018) An exploratory study: a head-to-head comparison of the EQ-5D-5L and AQoL-8D for long-term publicly waitlisted bariatric surgery patients before and 3 months after bariatric surgery. Pharmacoecon Open 2(4):443–458
Richardson J, Iezzi A, Khan MA, Maxwell A (2014) Validity and reliability of the assessment of quality of life (AQoL)-8D multi-attribute utility instrument. Patient 7(1):85–96
Luchman JN (2013) DOMIN: Stata module to conduct dominance analysis. https://ideas.repec.org/c/boc/bocode/s457629.html. Accessed 16 Apr 2018
Nathans LL, Oswald FL, Nimon K (2012) Interpreting multiple linear regression: a guidebook of variable importance. Pract Assess Rese Eval 17(9):1–19
Azen R, Budescu D (2003) The dominance analysis approach for comparing predictors in multiple regression. Psychol Methods 8:129–148
Azen R, Traxel N (2009) Using dominance analysis to determine predictor importance in logistic regression. J Educ Behav Stat 34:319–347
Greenland S (1989) Modeling and variable selection in epidemiologic analysis. Am J Public Health 79(3):340–349
Kamangar F (2012) Confounding variables in epidemiologic studies: basics and beyond. Arch Iran Med 15:508–516
Maxwell A, Özmen M, Iezzi A, Richardson J (2016) Deriving population norms for the AQoL-6D and AQoL-8D multi-attribute utility instruments from web-based data. Qual Life Res 25(12):3209–3219
Lo LMP, Taylor BV, Winzenberg T, Palmer A, Blizzard L, van der Mei I (2020) Comorbidities contribute substantially to the severity of common multiple sclerosis symptoms. J Neurol (Accepted)
Marrie RA (2018) Comorbidities in multiple sclerosis: a clinical resource guide. The Consortium of Multiple Sclerosis Centers (CMSC); Nurse Practitioner Alternatives (NPA); Catamount Medical Education. https://mscomorbidities.com/. Accessed 30 Mar 2018
Marrie RA, Patten SB, Tremlett H, Wolfson C, Warren S, Svenson LW, Jette N, Fisk J, Epidemiology CTit, Impact of Comorbidity on Multiple S, (2016) Sex differences in comorbidity at diagnosis of multiple sclerosis: A population-based study. Neurology 86(14):1279–1286. https://doi.org/10.1212/WNL.0000000000002481
Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T (2009) The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and undertreated. Mult Scler J 15(3):385–392
Woolf AD, Pfleger B (2003) Burden of major musculoskeletal conditions. Bull World Health Organ 81(9):646–656
Aitken D, Jones G, Winzenberg T (2019) Clinical overview of osteoarthritis (OA) and the challenges faced for future management. In. doi: 10.1016/B978–0–12–801238–3.11419–9
Degenhardt A, Ramagopalan SV, Scalfari A, Ebers GC (2009) Clinical prognostic factors in multiple sclerosis: a natural history review. Nat Rev Neurol 5(12):672–682
The authors would like to express their deepest gratitude for all the participants of the Australian Multiple Sclerosis Longitudinal Study for their continuous support and enthusiasm to respond to all surveys.
This study was supported by Multiple Sclerosis Research Australia.
Conflicts of interest
The authors declare that there are no conflicts of interest.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Lo, L.M.P., Taylor, B.V., Winzenberg, T. et al. Estimating the relative contribution of comorbidities in predicting health-related quality of life of people with multiple sclerosis. J Neurol 268, 569–581 (2021). https://doi.org/10.1007/s00415-020-10195-w
- Quality of life
- Multiple sclerosis
- General dominance analysis
- Relative contribution